Executive Summary / Key Takeaways

• The Outsourcing Acceleration Thesis: Arteris is capturing a fundamental shift where semiconductor companies are abandoning in-house system IP development due to soaring AI-driven complexity and a scarcity of qualified engineers, with over half of licensing dollars now tied to AI applications and major customers like AMD (AMD) and Altera standardizing on Arteris interconnects.

• Chiplet Architecture Multiplier: The industry’s pivot from monolithic SoCs to multi-die chiplet designs is expanding Arteris’s revenue opportunity per project, as each chiplet requires dedicated interconnect IP, turning what was once a single license into multiple revenue streams while lifting average selling prices.

• Profitability Inflection in Progress: With 90% gross margins, positive free cash flow in three of the last four quarters, and non-GAAP operating expenses held flat for three years, Arteris is demonstrating clear operating leverage that positions it to achieve sustainable profitability as revenue scales.

• Neutral IP Provider Advantage: As the only major independent interconnect IP vendor not tied to a processor or EDA ecosystem, Arteris offers chipmakers a flexible, mix-and-match solution that avoids vendor lock-in, a strategic moat that competitors like Arm , Synopsys , and Cadence cannot easily replicate.

• Critical Execution Variables: The investment thesis hinges on whether Arteris can convert its $104.7 million in remaining performance obligations into revenue faster than its cash burn, while navigating customer concentration risks and geopolitical headwinds that could impact 24% of revenue derived from China.

Setting the Scene: The Silent Enabler of AI Silicon

Arteris, Inc., incorporated in Delaware on April 12, 2004, and headquartered in Campbell, California, operates in one of the most critical yet overlooked segments of the semiconductor supply chain. The company develops, licenses, and supports on-chip interconnect fabric technology—Network-on-Chip (NoC) intellectual property—that functions as the central nervous system for complex System-on-Chip (SoC) designs. Every data packet moving between processors, memory, and I/O peripherals in modern chips flows through Arteris’s interconnects, making the company’s technology essential yet invisible to end consumers.

The semiconductor industry is undergoing a structural transformation driven by artificial intelligence. SoC designs have evolved from simple single-processor architectures to multi-core processors with cache coherency, then to AI-accelerated designs with massive internal data communication requirements, and now to disaggregated chiplet architectures . Each evolution has exponentially increased interconnect complexity, making in-house development prohibitively expensive and time-consuming. This is Arteris’s opportunity: as chip designs become more sophisticated, the addressable market for commercial system IP expands, with management estimating a total market of $1.0 to $1.2 billion.

Arteris occupies a unique position as a neutral, independent provider in an industry dominated by vertically integrated giants. Unlike Arm, which pushes its processor-centric AMBA interconnects , or Synopsys and Cadence, which bundle interconnect IP with their EDA tools, Arteris offers a vendor-agnostic solution that works across processor architectures—ARM, RISC-V, and x86. This neutrality matters deeply to customers who want to avoid ecosystem lock-in and maintain flexibility to mix-and-match best-in-class IP blocks. The company has shipped over 3.9 billion SoCs through its installed base, establishing silicon-proven credibility that reduces customer risk aversion for new designs.

Technology, Products, and Strategic Differentiation

Arteris’s competitive moat rests on two pillars: proprietary NoC technology and specialized deployment software that together reduce design time and improve power, performance, and area (PPA) efficiency . The company’s product portfolio includes FlexNoC for non-coherent interconnects, Ncore for cache-coherent designs, and the recently launched FlexGen Smart NoC IP, which automates NoC creation using AI-driven algorithms.

FlexGen represents a breakthrough in engineering productivity, reducing manual iteration by over 90% and delivering expert-level NoC topologies in hours instead of weeks. This matters because it directly addresses the industry-wide shortage of qualified hardware engineers. By automating the most complex aspects of interconnect design, FlexGen allows customers to accelerate time-to-market while reducing engineering headcount requirements. The product has been delivered to over 10 companies for evaluation, with management expecting revenue and ACV contribution in the second half of 2025. AMD’s licensing of FlexGen for high-performance data transport in AI chiplets, followed by additional incremental licenses in Q3 2025, validates the technology’s value proposition.

The physically aware FlexNoC 5, introduced in mid-2023, leverages advanced node and placement information to enable up to 5x faster physical coverage while supporting best-in-class PPA. By Q4 2024, over 75% of FlexNoC customers had adopted this advanced version, demonstrating rapid technology uptake. This physical awareness is critical as designs move to smaller process nodes where interconnect delay dominates performance. Arteris’s ability to optimize interconnects at the physical level provides measurable PPA improvements that customers cannot achieve with in-house solutions.

The Magillem acquisition in 2020 strategically complemented Arteris’s interconnect IP by adding SoC integration automation software. The latest generation of Magillem register management software, released in Q1 2025, provides a single source of data for hardware and software integration, mitigating silicon failure risks from outdated specifications. This software suite creates network effects in customer workflows, increasing switching costs and driving recurring support revenue.

Financial Performance & Segment Dynamics

Arteris’s financial results provide compelling evidence that the outsourcing thesis is materializing. In Q3 2025, total revenue grew 18% year-over-year to $17.4 million, driven by a 19% increase in licensing, support, and maintenance revenue to $15.9 million. More importantly, variable royalty revenue surged 28% to $1.5 million, with trailing 12-month royalties 36% higher year-over-year. Trailing 12-month royalties are growing significantly faster than licensing revenue, indicating that customers are successfully ramping production of SoCs incorporating Arteris IP.

The company’s business model exhibits exceptional unit economics. Gross margin held steady at 90% on a GAAP basis and 91% on a non-GAAP basis, reflecting the high-margin nature of IP licensing. While the company remains unprofitable on a GAAP basis with a net loss of $9 million in Q3, non-GAAP net loss was just $3.8 million, and the company generated positive free cash flow of $2.5 million. This marks the third quarter in the last four with positive free cash flow, demonstrating that the business can self-fund operations at current scale.

Annual Contract Value (ACV) plus royalties reached a record $74.9 million in Q3, up 24% year-over-year, while Remaining Performance Obligations (RPO) hit $104.7 million, up 34% year-over-year. These forward-looking metrics indicate strong revenue visibility and accelerating customer commitments. The 23 confirmed design starts in Q3 2025 versus 14 in the prior year period further corroborates that customers are increasingly outsourcing system IP to Arteris.

Segment dynamics reveal a powerful mix shift toward high-growth verticals. AI-related deals now account for over 55% of total business, with automotive and enterprise representing the two highest-growth verticals for ACV and royalties. Enterprise is the fastest-growing royalty segment, reflecting AI data center infrastructure needs. The automotive market accounts for roughly half of total royalties, providing a stable, long-cycle revenue base as design wins today translate to production royalties six to seven years later.

Competitive Context: The Independent Advantage

Arteris competes against three types of rivals: large EDA/IP companies (Synopsys, Cadence), processor IP vendors (Arm), and in-house development teams at semiconductor companies. Each competitor has inherent limitations that Arteris exploits.

Synopsys (SNPS) and Cadence (CDNS) dominate the EDA landscape with 13% and 10-12% overall semiconductor IP market share respectively. Their interconnect IP is tightly integrated with design tools, creating a seamless workflow for customers already embedded in their ecosystems. However, this integration comes at the cost of flexibility and premium pricing. Arteris’s standalone solutions offer comparable performance with greater configurability, appealing to customers who want to avoid tool lock-in. While Synopsys and Cadence can leverage their scale to offer bundled discounts, Arteris counters with specialized expertise and faster innovation cycles in pure interconnect technology.

Arm’s (ARM) 20-25% market share is built on processor-centric interconnects that work optimally within the Arm ecosystem. This creates a natural ceiling for Arm’s interconnect penetration in heterogeneous designs mixing multiple processor architectures. Arteris’s neutral positioning allows it to serve as the interconnect backbone for SoCs combining Arm cores with RISC-V, x86, or custom AI accelerators—a configuration increasingly common in AI workloads. The partnership with MIPS to provide a pre-verified RISC-V reference platform exemplifies this strategy.

The most significant competitive dynamic is the shift from internal development to commercial vendors. Charlie Janac notes that companies are designing their way out of recessions, and the scarcity of qualified engineers makes internal system IP development increasingly inefficient. Arteris amortizes R&D across hundreds of projects, achieving faster learning curves than any single internal team. This creates a 10x payback proposition for customers, driving the outsourcing trend that now represents Arteris’s core growth engine.

Outlook, Guidance, and Execution Risk

Management’s guidance for full-year 2025 reflects confidence tempered by macroeconomic uncertainty. ACV plus royalties is projected to exit 2025 at $74-78 million, representing 24% growth at the midpoint. Revenue guidance of $68.8-69.2 million implies 18% growth, while non-GAAP operating loss guidance of $12.5-13.5 million shows a clear path to profitability as revenue scales.

The guidance assumptions embed several key judgments. First, management expects the outsourcing trend to accelerate, with major customers increasing their system IP spend with Arteris. Second, they assume that geopolitical tensions and trade restrictions will not materially impact the 24% of revenue derived from China, though they acknowledge potential headwinds. Third, they expect the U.S. dollar to remain weak against the euro, increasing overseas expenses by approximately $1 million annually, but this is offset by other expense factors.

Execution risks center on three variables. Customer concentration remains high, with the top 10 customers representing a significant portion of revenue. The loss of a major customer could materially impact results. Second, the conversion of RPO to revenue must accelerate to sustain cash flow positivity. While RPO grew 34% year-over-year, the company must demonstrate consistent quarterly conversion. Third, FlexGen must successfully transition from evaluation to production deployments. With over 20 customer projects evaluating the technology, any delays in production ramp would push revenue recognition into 2026.

Risks and Asymmetries

The most material risk to the thesis is customer concentration. A significant portion of revenue derives from a limited number of licensees, making results vulnerable to a single key customer ceasing to use Arteris technology or experiencing a decline in product sales. This concentration amplifies the impact of design wins and losses, creating quarterly volatility that can mask underlying trends.

China exposure represents a geopolitical risk that management cannot fully control. With 24.4% of revenue derived from Chinese customers and U.S. export regulations tightening, revenue from this region is expected to decrease. The October 7, 2022 regulations and subsequent amendments impose restrictions on doing business with certain Chinese entities, potentially limiting Arteris’s ability to license or support products. While management has not adjusted guidance, they have widened revenue ranges to account for uncertainty.

The semiconductor industry’s cyclical nature poses a demand risk. Rapid technological change, product obsolescence, and supply/demand fluctuations can lead to significant downturns that affect customer spending on IP licenses. However, Charlie Janac argues that Arteris-type companies tend to do well in uncertain markets because customers design their way out of recessions, potentially insulating the company from the worst cyclical impacts.

Competition from larger players with substantially greater resources remains a constant threat. Synopsys, Cadence, and Arm can outspend Arteris on R&D and sales, and their integrated ecosystems create switching costs that favor incumbent vendors. Arteris’s neutral positioning is a double-edged sword: it avoids lock-in but also lacks the natural integration advantages of its larger rivals.

Valuation Context

At $19.67 per share, Arteris trades at an enterprise value-to-revenue multiple of 12.55x based on trailing twelve-month revenue of $57.7 million. This multiple reflects the market’s recognition of Arteris’s niche leadership while discounting for its smaller scale and lack of profitability.

Traditional earnings-based metrics are not meaningful given the company’s net losses and negative operating margin of -50%. Instead, investors should focus on the path to profitability signals. Gross margin of 90% is superior to all major competitors, indicating strong pricing power and unit economics. Non-GAAP operating expenses have remained broadly flat for three years while revenue grew 18%, demonstrating operating leverage.

The balance sheet provides adequate runway with $56.2 million in cash and no debt. Free cash flow turned positive in Q3 2025 at $2.5 million, and full-year guidance implies $2.5-5.5 million in free cash flow. This self-funding capability reduces dilution risk and validates the business model’s scalability.

Peer comparisons highlight the valuation opportunity and risk. Arm trades at 32.1x revenue with 97% gross margins and 34% revenue growth, commanding a premium for its royalty model and ecosystem dominance. Synopsys trades at 64.9x EBITDA with 81% gross margins, reflecting its EDA moat. Cadence trades at 17.5x revenue with 86% gross margins and 14% growth. Arteris’s 12.55x multiple appears reasonable for a company growing 18% with 90% gross margins, but the discount reflects execution risk and scale disadvantages.

Conclusion

Arteris stands at the intersection of three powerful semiconductor trends: the outsourcing of complex system IP, the proliferation of AI workloads requiring advanced interconnects, and the shift to chiplet architectures multiplying revenue opportunities per design. The company’s 90% gross margins, accelerating royalty growth, and recent free cash flow positivity provide tangible evidence that this thesis is materializing.

The central investment case hinges on whether Arteris can scale its specialized technology and neutral positioning into sustainable profitability before larger competitors replicate its innovations. With $104.7 million in RPO providing revenue visibility and over 20 FlexGen evaluations poised to convert to production revenue, the company has a clear path to growth. However, execution on customer concentration, China exposure, and competitive defense will determine whether Arteris captures a growing share of the $1.2 billion system IP market or remains a niche player vulnerable to consolidation.

For investors, the two variables to monitor are the conversion rate of RPO to revenue and the production ramp of FlexGen deployments. If Arteris can maintain its 18% growth trajectory while expanding operating margins, the current 12.55x revenue multiple may prove conservative. If execution falters, the company’s small scale and customer concentration could amplify downside risks in the cyclical semiconductor environment.